Qiagen's Q3 Revenues Climb 6 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen reported after the close of the market on Monday that revenues for the third quarter rose 6 percent year over year, with molecular diagnostics sales increasing 9 percent.

For the three months ended Sept. 30, the firm posted $274.3 million in sales, up from $259.7 million in the third quarter of 2009. Wall Street expected revenues of $276.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.